Camurus マネジメント

マネジメント基準チェック /44

Camurusの CEO はFredrik Tibergで、 Jan2003年に任命され、の在任期間は 21.83年です。は、会社の株式の2.82%を直接所有しており、その価値はSEK 928.77M 。経営陣と取締役会の平均在任期間はそれぞれ5.8年と4.5年です。

主要情報

Fredrik Tiberg

最高経営責任者

SEK 12.1m

報酬総額

CEO給与比率	n/a
CEO在任期間	21.8yrs
CEOの所有権	2.8%
経営陣の平均在職期間	5.8yrs
取締役会の平均在任期間	4.5yrs

経営陣の近況

Camurus AB (publ)'s (STO:CAMX) CEO Will Probably Have Their Compensation Approved By Shareholders

May 02

Recent updates

Investors Can Find Comfort In Camurus' (STO:CAMX) Earnings Quality

Nov 15

Camurus AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Nov 10

What Camurus AB (publ)'s (STO:CAMX) P/S Is Not Telling You

Aug 09

Earnings Miss: Camurus AB (publ) Missed EPS By 11% And Analysts Are Revising Their Forecasts

Jul 19

We Ran A Stock Scan For Earnings Growth And Camurus (STO:CAMX) Passed With Ease

Jul 12

Camurus AB (publ)'s (STO:CAMX) CEO Will Probably Have Their Compensation Approved By Shareholders

May 02

Need To Know: Analysts Are Much More Bullish On Camurus AB (publ) (STO:CAMX) Revenues

Nov 11

We Think Camurus' (STO:CAMX) Profit Is Only A Baseline For What They Can Achieve

Feb 22

CEO報酬分析

Camurus の収益と比較して、Fredrik Tiberg の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	SEK 266m
Jun 30 2024	n/a	n/a	SEK 223m
Mar 31 2024	n/a	n/a	SEK 450m
Dec 31 2023	SEK 12m	n/a	SEK 431m
Sep 30 2023	n/a	n/a	SEK 460m
Jun 30 2023	n/a	n/a	SEK 408m
Mar 31 2023	n/a	n/a	SEK 115m
Dec 31 2022	SEK 10m	SEK 6m	SEK 56m
Sep 30 2022	n/a	n/a	SEK 28m
Jun 30 2022	n/a	n/a	-SEK 13m
Mar 31 2022	n/a	n/a	-SEK 69m
Dec 31 2021	SEK 10m	SEK 6m	-SEK 90m
Sep 30 2021	n/a	n/a	-SEK 142m
Jun 30 2021	n/a	n/a	-SEK 156m
Mar 31 2021	n/a	n/a	-SEK 128m
Dec 31 2020	SEK 10m	SEK 5m	-SEK 167m
Sep 30 2020	n/a	n/a	-SEK 174m
Jun 30 2020	n/a	n/a	-SEK 216m
Mar 31 2020	n/a	n/a	-SEK 284m
Dec 31 2019	SEK 8m	SEK 5m	-SEK 290m
Sep 30 2019	n/a	n/a	-SEK 305m
Jun 30 2019	n/a	n/a	-SEK 286m
Mar 31 2019	n/a	n/a	-SEK 266m
Dec 31 2018	SEK 8m	SEK 5m	-SEK 235m
Sep 30 2018	n/a	n/a	-SEK 200m
Jun 30 2018	n/a	n/a	-SEK 208m
Mar 31 2018	n/a	n/a	-SEK 187m
Dec 31 2017	SEK 6m	SEK 4m	-SEK 191m

報酬と市場: Fredrikの総報酬 ($USD 1.10M ) は、 Swedish市場 ($USD 986.81K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Fredrikの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Fredrik Tiberg (61 yo)

21.8yrs

在職期間

SEK 12,056,000

報酬

Mr. Fredrik Tiberg has been Independent Director of Amniotics AB (publ) since 2021. He has been the Chief Executive Officer and President of Camurus AB (publ) since 2003. Mr. Tiberg serves as Chief Executi...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Fredrik Tiberg	President	21.8yrs	SEK 12.06m	2.82% SEK 928.8m
Jon U. Alonso	Chief Financial Officer	2.8yrs	データなし	0.0025% SEK 812.7k
Torsten Malmstrom	Chief Technology Officer	11.8yrs	データなし	0.060% SEK 19.8m
Rein Piir	Vice President of Investor Relations	9.8yrs	データなし	データなし
Bo A. TarrasWahlberg	VP of Legal & Group General Counsel	less than a year	データなし	データなし
Maria Lundqvist	Global Head of Human Resources	3.6yrs	データなし	データなし
Markus Johnsson	Senior Vice President of R&D	no data	データなし	0.036% SEK 11.7m
Fredrik Joabsson	Chief Business Development Officer	5.8yrs	データなし	0.068% SEK 22.4m
Richard Jameson	Chief Commercial Officer	8.4yrs	データなし	0.050% SEK 16.3m
Alberto Pedroncelli	Chief Medical Officer	1.4yrs	データなし	データなし

5.8yrs

平均在職期間

58yo

平均年齢

経験豊富な経営陣: CAMXの経営陣は経験豊富で経験豊富です（平均在職期間は5.8年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Fredrik Tiberg	President	22.8yrs	SEK 12.06m	2.82% SEK 928.8m
Jakob Lindberg	Independent Director	3.5yrs	SEK 350.00k	データなし
Per-Olof Wallstrom	Independent Chairman of the Board	14.8yrs	SEK 750.00k	0.17% SEK 57.2m
Behshad Sheldon	Independent Director	6.5yrs	SEK 350.00k	0.0017% SEK 559.4k
Hege Hellstrom	Independent Director	4.5yrs	SEK 375.00k	0.0055% SEK 1.8m
Stefan Persson	Director	2.5yrs	SEK 375.00k	0.0053% SEK 1.7m
Erika Johnsson	Director	1.5yrs	SEK 450.00k	0.0010% SEK 338.9k

4.5yrs

平均在職期間

59yo

平均年齢

経験豊富なボード: CAMXの取締役会は経験豊富であると考えられます ( 4.5年の平均在任期間)。

Camurus マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Camurus AB (publ), Annual General Meeting, May 27, 2025

President exercised options to buy kr81m worth of stock.

President recently sold kr39m worth of stock

Chief Technology Officer recently sold kr6.8m worth of stock

Chief Technology Officer recently sold kr845k worth of stock

Camurus AB (publ)'s (STO:CAMX) CEO Will Probably Have Their Compensation Approved By Shareholders

Recent updates

Investors Can Find Comfort In Camurus' (STO:CAMX) Earnings Quality

Camurus AB (publ), Annual General Meeting, May 27, 2025

Camurus AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Camurus AB (publ) to Report Q1, 2025 Results on May 15, 2025

Camurus Provides Regulatory Update on the US NDA for CAM2029 in Acromegaly

President exercised options to buy kr81m worth of stock.

President recently sold kr39m worth of stock

What Camurus AB (publ)'s (STO:CAMX) P/S Is Not Telling You

New minor risk - Insider selling

Chief Technology Officer recently sold kr6.8m worth of stock

Earnings Miss: Camurus AB (publ) Missed EPS By 11% And Analysts Are Revising Their Forecasts

Second quarter 2024 earnings: EPS misses analyst expectations

Camurus Announces Positive Phase 3 Results from the Acroinnova 2 Study of Octreotide Sc Depot (Cam2029) in Acromegaly Patients

We Ran A Stock Scan For Earnings Growth And Camurus (STO:CAMX) Passed With Ease

Camurus Announces the Publication in JAMA Network Open of A New Post H Holes Analysis from A 24-Week Randomized, Double-Blind, Phase 3 Study

Camurus Receives EMA Acceptance of MAA Filing for Octreotide SC Depot (Cam2029) for the Treatment of Acromegaly

Chief Technology Officer recently sold kr845k worth of stock

Consensus EPS estimates increase by 18%

First quarter 2024 earnings released: EPS: kr1.36 (vs kr1.06 in 1Q 2023)

Camurus AB (publ)'s (STO:CAMX) CEO Will Probably Have Their Compensation Approved By Shareholders

Investors Appear Satisfied With Camurus AB (publ)'s (STO:CAMX) Prospects

Camurus AB (Publ) Announces Board Resignations

Full year 2023 earnings: EPS misses analyst expectations

Camurus AB (Publ) Announces FDA Acceptance of NDA Submission for Oclaiz™ for Treatment of Acromegaly

Camurus' (STO:CAMX) Strong Earnings Are Of Good Quality

Consensus EPS estimates fall by 39%

With EPS Growth And More, Camurus (STO:CAMX) Makes An Interesting Case

Full year 2023 earnings: EPS misses analyst expectations

Camurus AB Provides Earnings Guidance for the Full Year 2024

Camurus AB Appoints Behshad Sheldon as President of Camurus Inc. and Member of the it's Executive Management Team, Starting 1 April 2024

Camurus AB (Publ) Completes Enrollment in the POSITANO Study of CAM2029 in Patients with Polycystic Liver Disease

Investor sentiment deteriorates as stock falls 15%

Price target increased by 8.2% to kr550

Camurus AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.09 billion.

Camurus AB (publ) Submits New Drug Application to the US FDA for Oclaiz for Treatment of Acromegaly

Camurus AB (publ) (STO:CAMX) Investors Are Less Pessimistic Than Expected

President exercised options to buy kr86m worth of stock.

Camurus AB Announces Completed Enrollment in the Phase 3 SORENTO Study of CAM2029 in Patients with Neuroendocrine Tumors

Price target increased by 16% to kr471

Investor sentiment improves as stock rises 20%

Need To Know: Analysts Are Much More Bullish On Camurus AB (publ) (STO:CAMX) Revenues

Camurus AB (publ) to Report Fiscal Year 2023 Results on Feb 15, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 9.1% to kr351

Camurus AB (Publ) Raises Earnings Guidance for the Year 2023

Camurus AB (publ), Annual General Meeting, May 08, 2024

Insider recently sold kr295k worth of stock

Camurus Announces US Launch of Brixadi for the Treatment of Moderate to Severe Opioid Use Disorder by Braeburn

Camurus AB (Publ) Provides Earnings Outlook for the Year 2023

New major risk - Earnings quality

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Camurus Announces New Phase 3 Data Recalling Long-Term Safety and Efficacy of Octreotide Sc Depot (Cam2029) in Patients with Acromegaly

Camurus Announces Positive Topline Results from A 24-Week Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial, Acromegaly

President recently sold kr23m worth of stock

Camurus Announces FDA Approval of Brixadi for the Treatment of Moderate to Severe Opioid Use Disorder

Consensus EPS estimates increase by 21%

Consensus EPS estimates increase by 25%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Camurus AB (Publ) Elects Erika Söderberg Johnsson as Board Member

We Think Camurus' (STO:CAMX) Profit Is Only A Baseline For What They Can Achieve

Price target decreased by 7.3% to kr287

Third quarter 2022 earnings released: EPS: kr0.63 (vs kr0.11 loss in 3Q 2021)

Consensus EPS estimates increase by 17%

Camurus AB (Publ) Provides Earnings Guidance for the Year 2023

Consensus forecasts updated

Camurus Announces PDUFA Date for Brixadi NDA for the Treatment of Opioid Use Disorder in the US

Forecast to breakeven in 2022

Price target increased to kr305

マネジメント基準チェック /44